Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
Ratings for Apellis Pharmaceuticals (NASDAQ:APLS) were provided by 15 analysts in the past three months, showcasing a mix…
Apellis Pharmaceuticals Refinances Existing Debt With Up To $475M Non-Dilutive Credit Facility
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liabilitySignificantly improves
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
In the latest quarter, 14 analysts provided ratings for Apellis Pharmaceuticals (NASDAQ:APLS), showcasing a mix of bullish and…
Expert Ratings For Apellis Pharmaceuticals
14 analysts have expressed a variety of opinions on Apellis Pharmaceuticals (NASDAQ:APLS) over the past quarter, offering a…
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today
Apellis Pharmaceuticals (NASDAQ:APLS) has outperformed the market over the past 5 years by 11.97% on an annualized basis…
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
Apellis Pharmaceuticals (NASDAQ:APLS) has outperformed the market over the past 5 years by 10.69% on an annualized basis…
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
Apellis Pharmaceuticals (NASDAQ:APLS) has been analyzed by 15 analysts in the last three months, revealing a diverse range…
$1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Apellis Pharmaceuticals (NASDAQ:APLS) has outperformed the market over the past 5 years by 24.05% on an annualized basis…
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
During the last three months, 16 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ:APLS), revealing diverse outlooks from…